Nov. 5, 2026—Siemens Healthineers has begun carving out its in vitro diagnostics business, with plans to launch it as a standalone company called Olyrian Diagnostics. The company will also change its name to Healthineers, with both changes happening in parallel.
Olyrian will focus on diagnostic solutions for laboratory and point-of-care testing, from patient draw to population health. The company describes its purpose as “powering human potential at the heart of care,” combining intelligent technology with the expertise of the people who make, interpret, and act on diagnostic information.
“Whether someone is running a test, interpreting a result, or deciding what happens next, informed and connected workflows help drive efficiency and empower a more comprehensive understanding of patient health,” Sharon Bracken, head of diagnostics for Siemens Healthineers, said in a press statement. “Olyrian Diagnostics is how we’ll define our next chapter.”
Olyrian will remain part of Siemens Healthineers during the transition, which is expected to be completed by mid-2028. As of today, there is no change to products and services, contracts, service levels, or customer points of contact.